We use cookies to improve your experience on our website. Read about how we use cookies and how you can control them by reviewing the Cookie section of our Privacy Policy. By continuing to use this website, you consent to our use of these cookies.
Search BMS Recruiting Clinical Trials
Interested in looking outside of BMS-sponsored trials?
Visit BolderScience.com to search all worldwide trials.
Choose filters to find specific trials in the BMS pipeline.
Clinical trial information is sourced from ClinicalTrials.gov. Information is updated manually as the clinical trials are published. The efficacy and safety of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.
Interested in looking outside of BMS-sponsored trials?
Visit BolderScience.com to search all worldwide trials.
Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants
Recruiting, Phase 2
NCT04572893A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnT (EMBARK-HFpEF)
Recruiting, Phase 2
NCT04766892Apixaban for the Acute Treatment of Venous Thromboembolism in Children
Recruiting, Phase 4
NCT02464969Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)
Recruiting, Phase 2
NCT04267393A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis
Recruiting, Phase 2
NCT04308681Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes
Recruiting, Phase 1
NCT04951778A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes
Recruiting, Phase 1
NCT02848001A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia
Recruiting, Phase 1/2
NCT04336982A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia
Recruiting, Phase 1/2
NCT04336982A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Recruiting, Phase 1
NCT05168202Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia
Recruiting, Phase 1
NCT04789655A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission
Recruiting, Phase 2
NCT05197426A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML)
Recruiting, Phase 1
NCT04887857A Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Recruiting, Phase 3
NCT04064060Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants Who Require Regular RBC Transfusions Due to Beta (β)-Thalassemia.
Recruiting, Phase 2
NCT04143724Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Recruiting, Phase 1/2
NCT03331198Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Recruiting, Phase 1/2
NCT03331198A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers
Recruiting, Phase 1
NCT03783403A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers
Recruiting, Phase 1
NCT03783403A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers
Recruiting, Phase 1
NCT03783403Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Recruiting, Phase 2/3
NCT03435796A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Recruiting, Phase 1
NCT05244070A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas
Recruiting, Phase 1
NCT02875223A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
Recruiting, Phase 1
NCT04860466A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Recruiting, Phase 1
NCT04231747A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Subjects With Relapsed or Refractory Non-hodgkin Lymphomas (R/R NHL)
Recruiting, Phase 1
NCT03930953A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Subjects With Relapsed or Refractory Non-hodgkin Lymphomas (R/R NHL)
Recruiting, Phase 1
NCT03930953A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Recruiting, Phase 1
NCT04434196Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
Recruiting, Phase 1
NCT04884035A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Subjects With Relapsed or Refractory Non-hodgkin Lymphomas (R/R NHL)
Recruiting, Phase 1
NCT03930953A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas
Recruiting, Phase 1
NCT04464798A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas
Recruiting, Phase 1
NCT04464798A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas
Recruiting, Phase 1
NCT04464798Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
Recruiting, Phase 1
NCT04884035Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)
Recruiting, Phase 1
NCT02631044A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM)
Recruiting, Phase 1/2
NCT03310619A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM)
Recruiting, Phase 1/2
NCT03310619A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM)
Recruiting, Phase 1/2
NCT03310619A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)
Recruiting, Phase 1/2
NCT03743246A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)
Recruiting, Phase 2
NCT04245839A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM)
Recruiting, Phase 1/2
NCT03310619A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM)
Recruiting, Phase 1/2
NCT03310619A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma (RELATIVITY-069)
Not Yet Recruiting, Phase 1/2
NCT05255601Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma
Recruiting, Phase 1
NCT04975399A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
Recruiting, Phase 1/2
NCT03989414A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
Recruiting, Phase 1/2
NCT03374085A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
Recruiting, Phase 1/2
NCT03989414A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
Recruiting, Phase 1/2
NCT03989414Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma
Recruiting, Phase 1
NCT03486067A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma
Recruiting, Phase 1
NCT04674813A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed and/or Refractory Multiple Myeloma
Recruiting, Phase 1
NCT04394650A Study of CC-99712, a BCMA Antibody-drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma
Recruiting, Phase 1
NCT04036461Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Not Yet Recruiting, Phase 3
NCT04975997A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 As Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
Recruiting, Phase 1/2
NCT02773030A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma
Recruiting, Phase 1/2
NCT02773030A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 As Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
Recruiting, Phase 1/2
NCT02773030A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma
Recruiting, Phase 1/2
NCT02773030A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma
Recruiting, Phase 1/2
NCT02773030A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 As Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
Recruiting, Phase 1/2
NCT02773030Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
Recruiting, Phase 3
NCT03651128An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-risk Multiple Myeloma
Recruiting, Phase 2
NCT03601078Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma
Recruiting, Phase 1/2
NCT04855136Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma
Recruiting, Phase 1/2
NCT04855136Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma
Recruiting, Phase 1/2
NCT04855136Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma
Recruiting, Phase 1/2
NCT04855136Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes
Recruiting, Phase 1
NCT04951778A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes
Recruiting, Phase 1
NCT02848001A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Recruiting, Phase 1
NCT05168202Efficacy and Safety Study of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Naļve Subjects Who Require Red Blood Cell Transfusions
Recruiting, Phase 3
NCT03682536An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell Transfusion
Recruiting, Phase 2
NCT03900715A Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Recruiting, Phase 3
NCT04064060A Study to Evaluate the Efficacy, Pharmacokinetics and Safety of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) in Chinese and Japanese Subjects With Ring Sideroblasts Who Require Red Blood Cell Transfusions
Recruiting, Phase 2
NCT04477850A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
Recruiting, Phase 1/2
NCT04817007A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
Recruiting, Phase 1/2
NCT04817007An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
Recruiting, Phase 3
NCT03952039A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
Recruiting, Phase 1/2
NCT04446650A Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Recruiting, Phase 3
NCT04064060An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
Recruiting, Phase 3
NCT04717414A Study of CC-99677 in Participants With Active Ankylosing Spondylitis
Recruiting, Phase 2
NCT04947579A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis
Recruiting, Phase 2
NCT05014438A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis
Recruiting, Phase 2
NCT05014438A Study to Evaluate the Long-term Safety and Efficacy of BMS-986165 in Participants With Crohn's Disease or Ulcerative Colitis
Recruiting, Phase 2
NCT04877990An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease
Recruiting, Phase 2
NCT03599622A Placebo-controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease
Recruiting, Phase 3
NCT03464097An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
Recruiting, Phase 3
NCT03467958Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
Recruiting, Phase 3
NCT03440372Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
Recruiting, Phase 3
NCT03440385A Study to Assess the Safety and Drug Levels of BMS-986256 in Participants With Active Cutaneous Lupus Erythematosus
Recruiting, Phase 1
NCT04493541A Study to Evaluate Efficacy and Safety of BMS-986165 in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
Recruiting, Phase 2
NCT04857034A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
Recruiting, Phase 3
NCT04753697Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
Recruiting, Phase 3
NCT04991935A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple Sclerosis
Recruiting, Phase 1
NCT05064436Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)
Recruiting, Phase 3
NCT04140305Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy
Recruiting, Phase 3
NCT05028634A Study to Evaluate the Drug Levels, Efficacy and Safety of BMS-986165 in Adolescent Participants With Moderate to Severe Plaque Psoriasis
Recruiting, Phase 3
NCT04772079A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naļve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment
Recruiting, Phase 3
NCT04908189A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naļve to Biologic Disease-modifying Anti-rheumatic Drugs
Recruiting, Phase 3
NCT04908202A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Recruiting, Phase 3
NCT04909801Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis
Recruiting, Phase 2
NCT04186871Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis
Recruiting, Phase 2
NCT04186871A Study Evaluating the Efficacy and Safety of BMS-986256 Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
Recruiting, Phase 2
NCT04895696Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis
Recruiting, Phase 2
NCT04186871A Study to Evaluate the Long-term Safety and Efficacy of BMS-986165 in Participants With Crohn's Disease or Ulcerative Colitis
Recruiting, Phase 2
NCT04877990A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative Colitis
Recruiting, Phase 2
NCT04613518To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis
Recruiting, Phase 3
NCT03915769A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
Recruiting, Phase 2/3
NCT05076175A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
Recruiting, Phase 3
NCT03661320Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer
Recruiting, Phase 3
NCT03036098A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
Recruiting, Phase 3
NCT04008030An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread
Recruiting, Phase 1/2
NCT03377361A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer (RELATIVITY-123)
Recruiting, Phase 3
NCT05328908A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Subjects Patients With Newly Diagnosed Glioblastoma
Recruiting, Phase 1
NCT04324840A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors
Recruiting, Phase 2
NCT04567615A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer
Recruiting, Phase 1
NCT03850067A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
Recruiting, Phase 3
NCT04025879A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer
Recruiting, Phase 2
NCT04702880A Study of Nivolumab and Ipilimumab in Untreated Patients With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery
Recruiting, Phase 3
NCT04026412A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
Recruiting, Phase 2
NCT04623775A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer
Not Yet Recruiting, Phase 2
NCT05005273A Study to Assess Adjuvant Immunotherapy With Relatlimab and Nivolumab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma (RELATIVITY-098)
Recruiting, Phase 3
NCT05002569A Study to Assess Safety and Efficacy of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment
Recruiting, Phase 1/2
NCT03978611A Study to Assess Adjuvant Immunotherapy With Relatlimab and Nivolumab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma (RELATIVITY-098)
Recruiting, Phase 3
NCT05002569A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection (CheckMate-6GE)
Recruiting, Phase 3
NCT05297565A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants
Recruiting, Phase 2
NCT05136677A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer
Recruiting, Phase 2
NCT05169684A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer
Recruiting, Phase 2
NCT05169684A Study of CC-90011 and Comparators in Participants With Prostate Cancer
Recruiting, Phase 1
NCT04628988Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer
Recruiting, Phase 1
NCT04428788A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer
Recruiting, Phase 3
NCT04100018A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread
Recruiting, Phase 3
NCT04810078A Combination Study of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India (CheckMate 7C9)
Recruiting, Phase 4
NCT04513522A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors
Recruiting, Phase 1
NCT05025085An Investigational Immuno-therapy Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Solid Cancers That Are Advanced or Have Spread
Recruiting, Phase 1/2
NCT02913313An Investigational Immuno-therapy Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Solid Cancers That Are Advanced or Have Spread
Recruiting, Phase 1/2
NCT02913313A Study to Assess Relatlimab in Combination With Nivolumab in Chinese Participants With Advanced Solid Tumors
Recruiting, Phase 1/2
NCT05134948First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors
Recruiting, Phase 1/2
NCT03110107An Investigational Immunotherapy Study of BMS-986249 Alone and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread
Recruiting, Phase 1/2
NCT03369223A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
Recruiting, Phase 1/2
NCT03400332An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
Recruiting, Phase 1/2
NCT03994601An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers
Recruiting, Phase 1
NCT03956680Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors
Recruiting, Phase 1/2
NCT04349267Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors
Recruiting, Phase 1/2
NCT04349267A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab in Participants With Advanced Solid Tumors
Recruiting, Phase 1/2
NCT04895709A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors
Recruiting, Phase 1
NCT05298592Dose Escalation of DF6002 in Patients With Advanced Solid Tumors, and Expansion in Selected Indications
Recruiting, Phase 1/2
NCT04423029A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
Recruiting, Phase 1
NCT04943900A Safety and Efficacy Study of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas
Recruiting, Phase 1
NCT02875223A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers
Recruiting, Phase 1
NCT03783403A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers
Recruiting, Phase 1
NCT03783403A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers
Recruiting, Phase 1
NCT03783403A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma
Recruiting, Phase 1
NCT04200963A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)
Recruiting, Phase 1/2
NCT03656718An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread
Recruiting, Phase 1/2
NCT03459222Looking for more clinical trials?
Bolder Science contains all clinical trials available on ClinicalTrials.gov, including BMS trials.
Visit BolderScience.com to search all trials worldwide.
Powered by ClinicalTrials.gov
: Development partnerships include:
1L=first line; 1L+=1L and above; 2L+=2L and above; 3L=third line; 3L+=3L and above; 4L=fourth line; 4L+=4L and above; AML=acute myeloid leukemia; AS=ankylosing spondylitis; axSpA=axial spondyloarthritis; B-ALL=B-cell acute lymphocytic leukemia; BH3=BCL-2 homology 3; B-NHL=B-cell non-Hodgkin lymphoma; BTK=Bruton’s tyrosine kinase; cCRT=concurrent chemoradiotherapy; CD=cluster of differentiation; CLL=chronic lymphocytic leukemia; CRC=colorectal cancer; CRPC=castration-resistant prostate cancer; DIPSS=Dynamic International Prognostic Scoring System; DLBCL=diffuse large B-cell lymphoma; DLE=discoid lupus erythematosus; DMARD=disease-modifying antirheumatic drug; dMMR=mismatch repair deficient; EGFR=epidermal growth factor receptor; ES-SCLC=extensive-stage small cell lung cancer; ESA=erythropoiesis-stimulating agent; ET=essential thrombocytopenia; EZH2=enhancer of zeste homolog 2; FL=follicular lymphoma; HCC=hepatocellular carcinoma; HL=Hodgkin lymphoma; HR-MDS=higher-risk myelodysplastic syndrome; Ide-cel=idecabtagene vicleucel; JAK=Janus kinase; Liso-cel=lisocabtagene maraleucel; mccRCC=metastatic clear-cell renal cell carcinoma; MCL=mantle cell lymphoma; mCRC=metastatic colorectal cancer; mCRPC=metastatic castration-resistant prostate cancer; MDS=myelodysplastic syndrome; MDS-RS=myelodysplastic syndrome with ring sideroblasts; MEK=mitogen-activated protein kinase; MF=myelofibrosis; MIBC=muscle-invasive bladder cancer; MM=multiple myeloma; MPN=myeloproliferative neoplasm; MSI-H=microsatellite instability-high; MZL=marginal zone lymphoma; NASH=nonalcoholic steatohepatitis; NDMM=newly diagnosed multiple myeloma; NHL=non-Hodgkin lymphoma; NSCLC=non-small cell lung cancer; PD-1=programmed death receptor-1; PD-L1=programmed death ligand 1; PMF=primary myelofibrosis; PsA=psoriatic arthritis; PV=polycythemia vera; RBCT=red blood cell transfusion; R/R=relapsed/refractory; RA=rheumatoid arthritis; RT=radiotherapy; SCLC=small cell lung cancer; SCLE=subacute cutaneous lupus erythematosus; SLL=small lymphocytic lymphoma; SpA=spondyloarthritis; TKI=tyrosine kinase inhibitor; TNFα=tumor necrosis factor alpha; UC=urothelial carcinoma; VTE=venous thromboembolism.
Use the form below to create one account that will be used across both BMS Science and Bolder Science. Clinical trials that you save on either site will be shown together on your dashboard on Bolder Science. If you already have an account, you can log in here.